Aurum Ventures Funds Development of Yissum Delivery Tech for Controlled-Release Oral Rxs

Aurum will provide $500,000 to Yissum for a pre-clinical feasibility study to see if the Hebrew University' delivery technology can be used to reformulate an intravenous cancer drug for oral administration.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.